Samer Al Hadidi/LinkedIn
Apr 28, 2025, 07:49
Samer Al Hadidi Highlights Improved Survival with IVIG in BCMA Bispecific Therapy for Myeloma
Samer Al Hadidi, Associate Professor at UAMS Myeloma Center, shared on X about a recent paper by Meera Mohan et al. published in Blood Cancer Journal:
“Check our recent publication led by Meera Mohan and Carolina Schinke Blood Cancer Journal multiple myeloma reporting on multi institution experience UAMS Myeloma Center
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma
IVIG use in patients on BCMA BsAbs was associated with improved infection free survival and overall survival
Prevention of infection is important in patients treated with those agents”
Authors: Meera Mohan et al.
In this update, Samer Al Hadidi highlighted a new publication from the UAMS Myeloma Center on the use of intravenous immunoglobulin (IVIG) in patients receiving BCMA-directed bispecific antibodies for multiple myeloma. The study showed that IVIG supplementation was linked to improved infection-free survival and overall survival, underscoring the importance of infection prevention in this patient population.
Read “Multiple Myeloma: Symptoms, Causes, Stages, Diagnosis and Treatment” insight on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 22:37
Sep 2, 2025, 22:03
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54